



**ASX Announcement**

## **Section 708A Cleansing Statement**

**Melbourne, Australia; 20 December 2024:**

This notice is given by Lumos Diagnostics Holdings Limited Ltd (ASX: LDX) (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) It has today issued 19,985 Fully Paid Ordinary Shares as the result of the cashless exercise of 31,250 unlisted options held by an employee of the Company;
- (b) the Shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

**<ENDS>**

This announcement has been approved by the Lumos Disclosure Committee.

###

### **About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com).*

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*



**Media Contact:**

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 (0) 423 139 163

**Investor Contact:**

Jane Lowe

Managing Director, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 117 774

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205, Australia

+61 3 9087 1598